AstraZeneca’s anti-IL-33 monoclonal antibody failed a Phase 2a study in chronic obstructive pulmonary disease, though the company noted there were still “encouraging clinical efficacy signals …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.